Queen카지노 게임 컬렉션�s 카지노게임사이트 pathologist David Berman plays a critical, if little-seen, role in a patient카지노 게임 컬렉션�s journey from medical consultation to disease diagnosis.

카지노 게임 컬렉션�I카지노 게임 컬렉션�m the one who looks at the patient카지노 게임 컬렉션�s tissues under a microscope and determines, this is benign, this is malignant,카지노 게임 컬렉션� he says. 카지노 게임 컬렉션�And if it카지노 게임 컬렉션�s malignant, I help answer important questions such as: does it need treatment and, if so, what kind? Or can this be left alone?카지노 게임 컬렉션�

As a clinician-scientist at the Kingston General Hospital Research Institute, Dr. Berman knows how difficult those decisions can be, especially in his research area of prostate cancer, where at least half of all diagnosed cases are harmless and don카지노 게임 컬렉션�t require treatment. And biopsies 카지노 게임 컬렉션� surgical procedures that remove small samples of tumor tissue for analysis 카지노 게임 컬렉션� aren카지노 게임 컬렉션�t always effective in distinguishing the harmful cancers from other, relatively harmless types.

카지노 게임 컬렉션�If we could find the biomarkers, or molecular clues, that would tell us which cancers are harmful, we could look for those features in blood or urine tests, and skip biopsies altogether,카지노 게임 컬렉션� he explains. 카지노 게임 컬렉션�Blood or urine tests would be faster, less expensive, and less invasive, and ensure that those with the more harmful cancers get their diagnosis and treatment sooner.카지노 게임 컬렉션�

His research is focused on doing just that. A recent recruit to the Queen카지노 게임 컬렉션�s Department of Pathology and Molecular Medicine and KGH from Johns Hopkins 카지노게임사이트 in Baltimore, Dr. Berman is leading a team of scientists across Canada who are studying a large number of genes that will form the foundation of new tests for prostate cancer. The group will study prostate cancer samples from two patient groups in Kingston and Montreal, looking for specific molecular features, such as the modification, gain or loss of particular genes.

The goal of this work, funded by and , is to develop new and better tests that help clarify decision-making for men newly diagnosed with prostate cancer, and improve their quality of life.

카지노 게임 컬렉션�There are some features for these tests that look really promising,카지노 게임 컬렉션� he says. 카지노 게임 컬렉션�We카지노 게임 컬렉션�re hoping to identify tests that will tell us at the time of biopsy whether the patient카지노 게임 컬렉션�s cancer is harmful.카지노 게임 컬렉션�

He카지노 게임 컬렉션�s happy with his progress so far, in part because of some distinct advantages in his research environment in Canada, he says. The first is Cancer Care Ontario카지노 게임 컬렉션�s patient registry, a computerized database that provides researchers with a wealth of scientific data about cancer diagnosis, treatment and outcomes for all Ontario cancer patients. 카지노 게임 컬렉션�It카지노 게임 컬렉션�s an advantage of Canada카지노 게임 컬렉션�s single-payer health care system,카지노 게임 컬렉션� he says. 카지노 게임 컬렉션�Johns Hopkins didn카지노 게임 컬렉션�t have anything like this.카지노 게임 컬렉션�

He also credits the NCIC Clinical Trials Group, literally next door, in the Queen카지노 게임 컬렉션�s Cancer Research Institute. 카지노 게임 컬렉션�Having the clinical trials group on site means we can take research to the next level by doing a patient trial.카지노 게임 컬렉션�

Dr. Berman was one of 14 researchers across Canada jointly awarded a five-year, $5 million Movember Team Grant from Prostate Cancer Canada. The team, called PRONTO, is focusing on rapid development of novel diagnostic markers for early prostate cancer.

This story is the third in a series on the KGH Research Institute and the clinician-scientists recruited to work in the centre.